Mainz Biomed B.V. (MYNZ): Price and Financial Metrics


Mainz Biomed B.V. (MYNZ): $7.80

-0.47 (-5.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYNZ Stock Summary

  • MYNZ's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.54 -- higher than only 4.96% of US-listed equities with positive expected earnings growth.
  • MYNZ's went public 1.08 years ago, making it older than just 0.9% of listed US stocks we're tracking.
  • With a price/sales ratio of 282.53, MAINZ BIOMED NV has a higher such ratio than 98.84% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to MAINZ BIOMED NV, a group of peers worth examining would be LFST, AREB, FAMI, KXIN, and SOPA.
  • To dig deeper into the stock's financial statements, go to MYNZ's page on browse-edgar?action=getcompany&CIK=0001874252.

MYNZ Valuation Summary

  • MYNZ's price/sales ratio is 299.5; this is 5890% higher than that of the median Healthcare stock.
  • MYNZ's price/earnings ratio has moved up 194.3 over the prior 13 months.

Below are key valuation metrics over time for MYNZ.

Stock Date P/S P/B P/E EV/EBIT
MYNZ 2022-12-02 299.5 5.0 -5.0 -4.0
MYNZ 2022-12-01 311.5 5.2 -5.2 -4.2
MYNZ 2022-11-30 317.5 5.3 -5.3 -4.3
MYNZ 2022-11-29 319.7 5.4 -5.3 -4.3
MYNZ 2022-11-28 325.7 5.5 -5.4 -4.4
MYNZ 2022-11-25 316.7 5.3 -5.3 -4.3

MYNZ Stock Price Chart Interactive Chart >

Price chart for MYNZ

MYNZ Price/Volume Stats

Current price $7.80 52-week high $30.00
Prev. close $8.27 52-week low $6.06
Day low $7.57 Volume 31,700
Day high $8.49 Avg. volume 170,309
50-day MA $7.45 Dividend yield N/A
200-day MA $10.39 Market Cap N/A

Mainz Biomed B.V. (MYNZ) Company Bio


Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.


MYNZ Latest News Stream


Event/Time News Detail
Loading, please wait...

MYNZ Latest Social Stream


Loading social stream, please wait...

View Full MYNZ Social Stream

Latest MYNZ News From Around the Web

Below are the latest news stories about MAINZ BIOMED NV that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.

Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leaderBERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs. In this role, Ms. Levin will be in char

Yahoo | November 29, 2022

Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

BERKELEY, Calif. and MAINZ, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable conferences in November and December 2022, Deutsches Eigenkapitalforum 2022 and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference. Deutsches Eigenkapit

Yahoo | November 22, 2022

Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert

eAArly DETECT expected to complete enrollment in Q1 2023 with results in 1H 2023Enhances ColoFuture’s demographic profile and expedites data read-out timelinePotential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to colorectal cancer (CRC) BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, anno

Yahoo | November 15, 2022

H.C. Wainwright Remains a Buy on Mainz Biomed B.V. (MYNZ)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Mainz Biomed B.V. (MYNZ - Research Report) today and set a price target of $25.00. The company's shares opened today at $7.50.Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Veru, and Aslan Pharmaceuticals. According to TipRanks, Chen has an average return of -24.1% and a 26.16% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mainz Biomed B.V. with a $20.00 average price target, implying a 166.67% upside from current levels.

Carrie Williams on TipRanks | November 3, 2022

Mainz Biomed Provides Third Quarter 2022 Update

BERKELEY, Calif. and MAINZ, Germany, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer today provided an update on accomplishments during the third quarter which ended September 30, 2022. Key Highlights and Recent Developments Expanded European and international commercial franchise for ColoAlert, the Company’s highly efficacious and easy-to-use DNA-based detecti

Yahoo | November 2, 2022

Read More 'MYNZ' Stories Here

MYNZ Price Returns

1-mo 10.80%
3-mo -10.24%
6-mo -28.90%
1-year -3.11%
3-year N/A
5-year N/A
YTD -24.93%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7441 seconds.